OSR Holdings announces update to $815M VXM01 licensing deal structure

OSR Holdings (OSRH) announced an updated structure of its previously disclosed binding term sheet dated January 13, 2026 with BCM Europe AG for the global licensing of its lead oncology asset VXM01. The revised structure is designed to improve capital efficiency and shift economic benefits directly to the parent company, OSR Holdings and its shareholders. Under the new framework, OSR Holdings will become a direct counterparty to the licensing agreement alongside its Swiss subsidiary, Vaximm AG, and an investment vehicle sponsored by BCM Europe AG. As part of this restructuring, up to $815 million in milestone payments, excluding royalties, will be payable directly to OSR Holdings rather than at the subsidiary level, reducing reliance on upstream distributions and simplifying the flow of funds. In parallel, OSR Holdings will provide a development financing facility of up to $30 million to Vaximm AG, which may be drawn as needed to support clinical development of VXM01.